BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 30598332)

  • 1. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
    Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
    Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD; Bannerman F; Beresford MW; Oni L
    BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.
    de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP
    Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Eculizumab as rescue therapy for lupus nephritis-related thrombotic microangiopathy].
    Fani FM; Patera A; Delsante M; Rossi GM; Manenti L; Landini S; Regolisti G; Fiaccadori E
    G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome.
    Geethakumari PR; Mille P; Gulati R; Nagalla S
    Transfus Apher Sci; 2017 Jun; 56(3):400-403. PubMed ID: 28428030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab.
    El-Husseini A; Hannan S; Awad A; Jennings S; Cornea V; Sawaya BP
    Am J Kidney Dis; 2015 Jan; 65(1):127-30. PubMed ID: 25446020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature.
    Skoczynska M; Crowther MA; Chowaniec M; Ponikowska M; Chaturvedi S; Legault K
    Lupus; 2020 May; 29(6):631-639. PubMed ID: 32252584
    [No Abstract]   [Full Text] [Related]  

  • 9. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.
    Kim MJ; Lee H; Kim YH; Jin SY; Kim HJ; Oh D; Jeon JS
    BMC Nephrol; 2021 Mar; 22(1):86. PubMed ID: 33691638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.
    Abe T; Sasaki A; Ueda T; Miyakawa Y; Ochiai H
    Medicine (Baltimore); 2017 Feb; 96(6):e6056. PubMed ID: 28178155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.
    Fujita Y; Terashita M; Yazawa M; Yamasaki Y; Imamura T; Kibayashi J; Sawai T; Hidaka Y; Ohtani K; Inoue N; Shibagaki Y
    Intern Med; 2020; 59(1):93-99. PubMed ID: 31902910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
    Sciascia S; Radin M; Yazdany J; Tektonidou M; Cecchi I; Roccatello D; Dall'Era M
    Rheumatol Int; 2017 Aug; 37(8):1249-1255. PubMed ID: 28258475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.
    Kotzen ES; Roy S; Jain K
    Adv Chronic Kidney Dis; 2019 Sep; 26(5):376-386. PubMed ID: 31733722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
    Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.
    Hadaya K; Ferrari-Lacraz S; Fumeaux D; Boehlen F; Toso C; Moll S; Martin PY; Villard J
    Am J Transplant; 2011 Nov; 11(11):2523-7. PubMed ID: 21831149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis.
    Øzbay LA
    Clin J Gastroenterol; 2020 Jun; 13(3):344-348. PubMed ID: 31612381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report.
    Nakamura M; Abe T; Ochiai H
    Am J Case Rep; 2022 Jun; 23():e936116. PubMed ID: 35671252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
    Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.